# US 2021/0330615 A1 · S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330615 A1
- Document ID: US20210330615A1
- Status: Published application
- Kind: A1
- Application number: 17/231,789
- Filed: 2021-04-15
- Published: 2021-10-28
- Earliest claimed: 2013-03-14
- Assignees: Actimed Therapeutics Limited
- Applicants: Actimed Therapeutics Limited
- Inventors: Andrew J.S. COATS; Stefan ANKER; Jochen SPRINGER
- Web page: https://patentgrep.com/patent/US20210330615A1

## CPC

- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can also be used for preventing loss of lean mass, preventing body weight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A method of increasing locomotive activity in an individual having amyotrophic lateral sclerosis, comprising administering to the individual an effective amount of a composition comprising a beta blocker which is oxprenolol or a pharmaceutically acceptable salt thereof, wherein the composition is enantiomerically enriched for the S-enantiomer of the beta-blocker.

### Claim at position 2

-7. (canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein the composition comprises an enantiomeric excess of at least about 50% of S-oxprenolol.

### Claim 9 (depends on 8)

The method of claim 8, wherein the composition comprises an enantiomeric excess of at least about 80% of S-oxprenolol.

### Claim 10 (depends on 9)

The method of claim 9, wherein the composition comprises an enantiomeric excess of at least about 99% of S-oxprenolol.

### Claim 11 (depends on 10)

The method of claim 10, wherein the composition comprises an enantiomeric excess of at least 99.9% of S-oxprenolol.

### Claim 12 (depends on 1)

The method of claim 1, wherein the amyotrophic lateral sclerosis is sporadic amyotrophic lateral sclerosis.

### Claim 13 (depends on 1)

The method of claim 1, wherein the amyotrophic lateral sclerosis is familial amyotrophic lateral sclerosis.

### Claim 14 (depends on 1)

The method of claim 1, wherein the amyotrophic lateral sclerosis is Western Pacific amyotrophic lateral sclerosis.

### Claim 15 (depends on 1)

The method of claim 1, wherein the amyotrophic lateral sclerosis is juvenile amyotrophic lateral sclerosis.

### Claim 16 (depends on 1)

The method of claim 1, wherein the amyotrophic lateral sclerosis is Hiramaya Disease.

### Claim 17 (depends on 1)

The method of claim 1, wherein the amyotrophic lateral sclerosis is progressive bulbar palsy (PBP), progressive muscular atrophy (PMA), primary lateral sclerosis (PLS), or ALS with multi-system involvement.

### Claim 18 (depends on 1)

The method of claim 1, wherein the composition is administered orally.

### Claim 19 (depends on 1)

The method of claim 1, wherein the amount of S-oxprenolol in the composition is about 80 to about 160 mg daily.

### Claim 20 (depends on 1)

The method of claim 1, wherein the composition is administered daily or twice daily.

### Claim at position 16

-22. (canceled)